454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples

: Detection of KRAS mutations in archival pathology samples is critical for therapeutic appropriateness of anti-EGFR monoclonal antibodies in colorectal cancer. We compared the sensitivity, specificity, and accuracy of Sanger sequencing, ARMS-Scorpion (TheraScreen ® ) real-time polymerase chain reaction (PCR), pyrosequencing, chip array hybridization

[1]  F. López-Ríos,et al.  A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens , 2012, British Journal of Cancer.

[2]  L. Terracciano,et al.  KRAS Mutation Testing in Colorectal Cancer: Comparison of the Results Obtained Using 3 Different Methods for the Analysis of Codons G12 and G13 , 2012, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[3]  S. Soviero,et al.  Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma , 2011, Virchows Archiv.

[4]  Yi-long Wu,et al.  Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Wu,et al.  KRAS mutation detection in colorectal cancer by a commercially available gene chip array compares well with Sanger sequencing. , 2011, Clinica chimica acta; international journal of clinical chemistry.

[6]  I. Soubeyran,et al.  The detection of double mutations in KRAS depends on the mutation-detection assay used. , 2011, Clinical chemistry.

[7]  C. Bokemeyer,et al.  Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  E. Van Cutsem,et al.  Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  T. Trikalinos,et al.  Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced Colorectal Cancer , 2011, Annals of Internal Medicine.

[10]  K. Edlund,et al.  KRAS analysis in colorectal carcinoma: Analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice , 2010, BMC Cancer.

[11]  L. Shen,et al.  Comparative analysis of dideoxy sequencing, the KRAS StripAssay and pyrosequencing for detection of KRAS mutation. , 2010, World journal of gastroenterology.

[12]  A. Grothey,et al.  Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer , 2009, Clinical Cancer Research.

[13]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[14]  A. Jimeno,et al.  KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Sabine Tejpar,et al.  KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience , 2008 .

[16]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Ronaghi,et al.  A Sequencing Method Based on Real-Time Pyrophosphate , 1998, Science.

[18]  A. Jimeno,et al.  KRAS mutation: comparison of testing methods and tissue sampling techniques in colon cancer. , 2010, The Journal of molecular diagnostics : JMD.

[19]  Joanne Cross.  DxS Ltd. , 2008, Pharmacogenomics (London).

[20]  P. Jares,et al.  KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program , 2008, Virchows Archiv.